Accéder au contenu
Merck
  • Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study.

Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study.

European journal of obstetrics, gynecology, and reproductive biology (2014-12-03)
Matteo Morotti, Valentino Remorgida, Pier Luigi Venturini, Simone Ferrero
RÉSUMÉ

To evaluate the effect of a desogestrel progestogen-only pill (POP) compared to continuous combined oral contraception (COC) on migraine patterns in women with migraine without aura. A retrospective analysis of prospective headache charts from migrainous women who used the POP or COC in our clinic between July 2009 and July 2013. The quality and quantity of migraine attacks and use of medications were evaluated at three and six months. Health related quality of life was evaluated after 6 months' treatment. Fifty-three patients were evaluable for the analysis (22 in the COC group and 31 in the POP group). Six months' POP treatment led to a statistical reduction in migraine days; headache days; pain intensity; number of days with severe pain and days with pain medication. The only statistical difference between the two groups was a reduction in the number of days with pain medication in the POP group compared to the COC group (p=0.044). After 6 months' treatment a quality of life improvement was seen only in the POP group, but no statistical differences were found when comparing the two groups. Our preliminary data confirm that POP therapy improves migraine patterns and quality of life after 6 months' treatment in women with migraine without aura and it decreases the analgesic consumption with respect to an extended COC therapy. As POP represents a healthier opportunity, in terms of vascular risk, than combined contraception, its role in migrainous women deserves to be further investigated.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
17α-Ethynylestradiol, ≥98%
USP
17α-Ethynylestradiol, United States Pharmacopeia (USP) Reference Standard
Supelco
17α-Ethynylestradiol, Pharmaceutical Secondary Standard; Certified Reference Material
17α-Ethynylestradiol, European Pharmacopoeia (EP) Reference Standard
17α-Ethynylestradiol, British Pharmacopoeia (BP) Assay Standard
17α-Ethynylestradiol, European Pharmacopoeia (EP) Reference Standard
Desogestrel, European Pharmacopoeia (EP) Reference Standard
Desogestrel, European Pharmacopoeia (EP) Reference Standard